Sanofi reports positive Phase III extension results for Toujeo in Japanese patients

8 June 2015

Sanofi (Euronext: SAN) announced positive results for its Toujeo (insulin glargine [rDNA origin] injection) in a Phase III study extension in Japanese people with uncontrolled diabetes.

The company presented results from the EDITION JP 1 and EDITION JP 2 extension studies at the American Diabetes Association meeting. Japanese participants with type 1 and type 2 diabetes received Toujeo or Lantus (insulin glargine) treatment for 12 months. Over the entire study period, Toujeo maintained similar blood sugar control, and fewer patients experienced night-time low blood sugar events compared with Lantus. Toujeo is a follow-on drug to Lantus, which is soon to lose patent protection. Sanofi has said it will not offer Toujeo at a discount to Lantus.

Toujeo presents diabetes advantage over Lantus

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK